Drug search by name

Immune Globulin Injection (Subcutaneous) and Thrombosis

Result of checking the interaction of drug Immune Globulin Injection (Subcutaneous) and disease Thrombosis for safety when used together.

Check result:

Immune Globulin Injection (Subcutaneous) <> Thrombosis

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Thrombosis has been reported after treatment with immune globulin products. In general, patients at greatest risk of thromboembolic events are those of advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors; therefore, it is recommended that patients treated with these agents should be monitored for signs and symptoms of thrombosis and assess blood viscosity in patients at risk. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity.

Immune Globulin Injection (Subcutaneous)

Generic Name: immune globulin subcutaneous

Brand Name: Cutaquig, Cuvitru, Hizentra, Vivaglobin, Xembify

Synonyms: Immune globulin (subcutaneous)

What is Immune Globulin Injection (Subcutaneous)?